Received Approval for Clinical Trial of Innovative Anti-tumor Drug SHR-1049 Injection
January 27, 2026
Source: drugdu
47
Hengrui Pharma Announcement (January 26): The company has received a "Notice of Approval for Drug Clinical Trial" from the NMPA for SHR-1049 Injection, approving clinical trials of the drug as a monotherapy for advanced solid tumors. SHR-1049 Injection is an innovative anti-tumor drug independently developed by the company, intended for the treatment of advanced solid tumors. According to current research, no similar drugs have been approved for marketing both domestically and internationally.
https://finance.eastmoney.com/a/202601263630701956.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Strategic Collaboration with AstraZeneca, Potential Transaction Value Up to $18.5 Billion January 31, 2026
- Farsight Medical Announces First Patient Dosed in Phase II Clinical Trial of RN-0001, a World-First Therapy for Acute Pancreatitis January 31, 2026
- Boao Lecheng CGT project reaches 20 items! The first autologous NK therapy for eight types of cancer in China has been approved, costing 49,800 yuan per treatment January 31, 2026
- Yangtze River Pharmaceutical Group is ramping up its investment in the 10 billion yuan contrast agent market, aiming to challenge Hengrui January 31, 2026
- Simcere Pharmaceutical’s TL1A/IL-23p19 bispecific antibody goes global, partnering with Boehringer Ingelheim to expand the global inflammatory bowel disease market. January 31, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
